IQVIA (IQV) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
27 Feb, 2026Executive summary
Annual meeting scheduled for April 23, 2026, at Hotel Zero Degrees, Danbury, Connecticut, with voting available online or in person until April 22, 2026.
Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of nine directors, each recommended by the board.
Advisory vote on executive compensation (say-on-pay) recommended for approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 recommended for approval.
Approval of the 2026 Incentive and Stock Award Plan recommended for approval.
Stockholder proposal to separate Chairman and CEO roles recommended against by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Board opposes a shareholder proposal to split Chairman and CEO roles.
Latest events from IQVIA
- AI adoption, biotech growth, and new acquisitions drive optimism and margin expansion.IQV
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - AI-driven efficiencies and the Cedar Gate acquisition strengthen patient analytics and growth.IQV
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 results show robust growth, innovation, and governance, with all management proposals recommended.IQV
Proxy Filing27 Feb 2026 - Strong Q4 growth, stable margins, and AI-driven opportunities support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Strong 2025 results and 2026 outlook driven by AI, segment realignment, and robust demand.IQV
Q4 20255 Feb 2026 - Q2 revenue and profit margins rose, with record backlog and reaffirmed full-year guidance.IQV
Q2 20243 Feb 2026 - Strong R&DS and data-driven AI offset TAS volatility, supporting robust margins and growth outlook.IQV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 4.3%, adjusted EPS up 14.1%, with strong TAS growth and $31.1B backlog.IQV
Q3 202417 Jan 2026 - Q3 outperformed on TAS growth, but R&DS bookings faced headwinds from cancellations and delays.IQV
UBS Global Healthcare Conference 202414 Jan 2026